Accolade to Focus on Allergic Eye Disorders

June 1, 2020

In an effort to focus the development of topical zafirlukast, the company has decided to concentrate resources on the application fro allergic eye disorders.  The decision was based on the preclinical experiments in animal models of conjunctivitis as well as the compelling clinical results assessing oral use of LTRAs by major companies which indicate significant room for improved efficacy with a topical formulation for teh eye.        

Please reload

©  2020 Accolade Pharma, LLC

42 Hill Road

Wilmington, DE 19806

302-427-2985